Tracy L Greer1, Joseph M Trombello2, Chad D Rethorst2, Thomas J Carmody2,3, Manish K Jha2, Allen Liao2, Bruce D Grannemann2, Heather O Chambliss, Timothy S Church4, Madhukar H Trivedi2. 1. Center for Depression Research and Clinical Care, Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, Texas. tracy.greer@utsouthwestern.edu. 2. Center for Depression Research and Clinical Care, Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, Texas. 3. Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas. 4. Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana.
Abstract
BACKGROUND: Functional impairments often remain despite symptomatic improvement with antidepressant treatment, supporting the need for novel treatment approaches. The present study examined the extent to which exercise augmentation improved several domains of psychosocial functioning and quality of life (QoL) among depressed participants. METHODS: Data were collected from 122 partial responders to antidepressant medication. Participants were randomized to either high- (16 kcal/kg of weight/week [KKW]) or low-dose (4-KKW) exercise. Participants completed a combination of supervised and home-based exercise for 12 weeks. The Short-Form Health Survey, Work and Social Adjustment Scale, Social Adjustment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Satisfaction with Life Scale were collected at 6 and 12 weeks. Participants with data for at least one of the two follow-up time points (n = 106) were analyzed using a linear mixed model to assess change from baseline within groups and the difference between groups for each psychosocial outcome measure. All analyses controlled for covariates, including baseline depressive symptomatology. RESULTS: Participants experienced significant improvements in functioning across tested domains, and generally fell within a healthy range of functioning on all measures at Weeks 6 and 12. Although no differences were found between exercise groups, improvements were observed across a variety of psychosocial and QoL domains, even in the low-dose exercise group. CONCLUSIONS: These findings support exercise augmentation of antidepressant treatment as a viable intervention for treatment-resistant depression to improve function in addition to symptoms.
RCT Entities:
BACKGROUND:Functional impairments often remain despite symptomatic improvement with antidepressant treatment, supporting the need for novel treatment approaches. The present study examined the extent to which exercise augmentation improved several domains of psychosocial functioning and quality of life (QoL) among depressedparticipants. METHODS: Data were collected from 122 partial responders to antidepressant medication. Participants were randomized to either high- (16 kcal/kg of weight/week [KKW]) or low-dose (4-KKW) exercise. Participants completed a combination of supervised and home-based exercise for 12 weeks. The Short-Form Health Survey, Work and Social Adjustment Scale, Social Adjustment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Satisfaction with Life Scale were collected at 6 and 12 weeks. Participants with data for at least one of the two follow-up time points (n = 106) were analyzed using a linear mixed model to assess change from baseline within groups and the difference between groups for each psychosocial outcome measure. All analyses controlled for covariates, including baseline depressive symptomatology. RESULTS:Participants experienced significant improvements in functioning across tested domains, and generally fell within a healthy range of functioning on all measures at Weeks 6 and 12. Although no differences were found between exercise groups, improvements were observed across a variety of psychosocial and QoL domains, even in the low-dose exercise group. CONCLUSIONS: These findings support exercise augmentation of antidepressant treatment as a viable intervention for treatment-resistant depression to improve function in addition to symptoms.
Authors: E Heyman; F-X Gamelin; M Goekint; F Piscitelli; B Roelands; E Leclair; V Di Marzo; R Meeusen Journal: Psychoneuroendocrinology Date: 2011-10-24 Impact factor: 4.905
Authors: Ira H Bernstein; A John Rush; Carmody J Thomas; Ada Woo; Madhukar H Trivedi Journal: Neuropsychiatr Dis Treat Date: 2006-12 Impact factor: 2.570
Authors: Heidemarie Lex; Yarden Ginsburg; Adam F Sitzmann; Clara Grayhack; Daniel F Maixner; Brian J Mickey Journal: J Affect Disord Date: 2018-09-19 Impact factor: 4.839
Authors: Lisa A Uebelacker; Marie A Sillice; Gary Epstein-Lubow; Cynthia L Battle; Bradley Anderson; Celeste Caviness; Ivan W Miller; Ana M Abrantes Journal: Contemp Clin Trials Date: 2020-03-07 Impact factor: 2.226
Authors: Chad D Rethorst; Charles C South; A John Rush; Tracy L Greer; Madhukar H Trivedi Journal: Depress Anxiety Date: 2017-07-03 Impact factor: 6.505
Authors: Manish K Jha; Abu Minhajuddin; Tracy L Greer; Thomas Carmody; Augustus John Rush; Madhukar H Trivedi Journal: PLoS One Date: 2016-12-28 Impact factor: 3.240
Authors: Manish K Jha; Abu Minhajuddin; Charles South; A John Rush; Madhukar H Trivedi Journal: Int J Neuropsychopharmacol Date: 2018-04-01 Impact factor: 5.176
Authors: Laura E Keating; Suzanna Becker; Katie McCabe; Jeff Whattam; Laura Garrick; Benicio N Frey; Roberto B Sassi; Margaret C McKinnon Journal: BMJ Open Sport Exerc Med Date: 2019-05-21
Authors: Laura E Keating; Suzanna Becker; Katie McCabe; Jeff Whattam; Laura Garrick; Roberto B Sassi; Benicio N Frey; Margaret C McKinnon Journal: BMJ Open Sport Exerc Med Date: 2018-06-15